• Expanded partnership with University of Chicago Medicine, becoming 5th US AMC to adopt CT:VQ™
• Commenced 90-day evaluation of CT:VQ™ at Mayo Clinic, the #1 US hospital
• Secured contract with GlaxoSmithKline for quantitative lung imaging analytics

4DMedical reported significant commercial momentum for its CT:VQ™ technology in Q3 FY26, with the University of Chicago Medicine becoming the fifth leading US Academic Medical Centre (AMC) to commercially adopt the solution. The company also commenced a 90-day evaluation of CT:VQ™ at Mayo Clinic, consistently ranked the number one hospital in the US. Additionally, 4DMedical secured a contract with GlaxoSmithKline to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development. The company achieved key regulatory milestones, including CE Mark certification for CT:VQ™ enabling commercial deployment across the European Union, and UKCA certification for the UK market. 4DMedical also received Canadian regulatory clearance for its Coronary Artery Calcium (CAC) analysis solution. The quarter saw the completion of two institutional placements totalling $233 million, strengthening the company's balance sheet and supporting its commercial expansion plans. 4DMedical was also included in the S&P/ASX 200 Index, reflecting its significant progress over the past year.

Underlying SaaS revenue up 24% YTD FY26 vs prior corresponding period, with Q3 customer receipts up 18% vs prior corresponding period.

4DMedical is focused on winning thought leadership in its sector, as evidenced by securing contracts with leading sites across the US. This creates a network effect and lays the foundation for powerful growth in scan volumes as the company heads into calendar 2027.